Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Fátima Cardoso, Shani Paluch‐Shimon, Elżbieta Senkus, et al.
Annals of Oncology (2020) Vol. 31, Iss. 12, pp. 1623-1649
Open Access | Times Cited: 1087

Showing 1-25 of 1087 citing articles:

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
Alessandra Gennari, Fabrice André, Carlos H. Barrios, et al.
Annals of Oncology (2021) Vol. 32, Iss. 12, pp. 1475-1495
Open Access | Times Cited: 864
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
Javier Cortés, Sung-Bae Kim, Wei‐Pang Chung, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 12, pp. 1143-1154
Open Access | Times Cited: 808
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer
Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 10, pp. 942-950
Open Access | Times Cited: 480
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
Leisha A. Emens, Sylvia Adams, Carlos H. Barrios, et al.
Annals of Oncology (2021) Vol. 32, Iss. 8, pp. 983-993
Open Access | Times Cited: 339
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
Nadia Harbeck, Priya Rastogi, Miguel Martín, et al.
Annals of Oncology (2021) Vol. 32, Iss. 12, pp. 1571-1581
Open Access | Times Cited: 313
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
Hope S. Rugo, Florence Lerebours, Eva Ciruelos, et al.
The Lancet Oncology (2021) Vol. 22, Iss. 4, pp. 489-498
Closed Access | Times Cited: 296
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
Paolo Tarantino, Roberto Carmagnani Pestana, Chiara Corti, et al.
CA A Cancer Journal for Clinicians (2021) Vol. 72, Iss. 2, pp. 165-182
Open Access | Times Cited: 282
Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial
F. Mosele, Élise Deluche, Amélie Lusque, et al.
Nature Medicine (2023) Vol. 29, Iss. 8, pp. 2110-2120
Open Access | Times Cited: 196
Evolution of HER2-low expression from primary to recurrent breast cancer
Federica Miglietta, Gaia Griguolo, Michele Bottosso, et al.
npj Breast Cancer (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 169
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis
Giuseppe Curigliano, Volkmar Mueller, Virginia F. Borges, et al.
Annals of Oncology (2021) Vol. 33, Iss. 3, pp. 321-329
Open Access | Times Cited: 161
Current and Future Management of HER2-Positive Metastatic Breast Cancer
Olga Martínez‐Sáez, Aleix Prat
JCO Oncology Practice (2021) Vol. 17, Iss. 10, pp. 594-604
Closed Access | Times Cited: 152
Unmet supportive care needs of people with advanced cancer and their caregivers: A systematic scoping review
Nicolas H. Hart, Fiona Crawford‐Williams, Megan Crichton, et al.
Critical Reviews in Oncology/Hematology (2022) Vol. 176, pp. 103728-103728
Closed Access | Times Cited: 145
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative
Philippe Aftimos, Mafalda Oliveira, Alexandre Irrthum, et al.
Cancer Discovery (2021) Vol. 11, Iss. 11, pp. 2796-2811
Open Access | Times Cited: 131
Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis
Avirup Guha, Michael G. Fradley, Susan Dent, et al.
European Heart Journal (2021) Vol. 43, Iss. 4, pp. 300-312
Open Access | Times Cited: 117
ESO–ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)
Shani Paluch‐Shimon, Fátima Cardoso, Ann H. Partridge, et al.
Annals of Oncology (2022) Vol. 33, Iss. 11, pp. 1097-1118
Open Access | Times Cited: 114
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial
Sacha J. Howell, Angela Casbard, Margherita Carucci, et al.
The Lancet Oncology (2022) Vol. 23, Iss. 7, pp. 851-864
Open Access | Times Cited: 110
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
Laura Morrison, Sibylle Loibl, Nicholas C. Turner
Nature Reviews Clinical Oncology (2023) Vol. 21, Iss. 2, pp. 89-105
Closed Access | Times Cited: 109
Immunotherapy for early triple negative breast cancer: research agenda for the next decade
Paolo Tarantino, Chiara Corti, Peter Schmid, et al.
npj Breast Cancer (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 107
Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer
Karen Van Baelen, Tatjana Geukens, Marion Maetens, et al.
Annals of Oncology (2022) Vol. 33, Iss. 8, pp. 769-785
Open Access | Times Cited: 84
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3
M.P. Goetz, M. Toi, Jens Huober, et al.
Annals of Oncology (2024) Vol. 35, Iss. 8, pp. 718-727
Open Access | Times Cited: 80
A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy
Federico Riccardi, Michele Dal Bo, Paolo Macor, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 76
An emerging generation of endocrine therapies in breast cancer: a clinical perspective
Rima Patel, Paula Klein, Amy Tiersten, et al.
npj Breast Cancer (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 70
What Is Known about Breast Cancer in Young Women?
Jie Wei Zhu, Parsa Charkhchi, Shadia Adekunte, et al.
Cancers (2023) Vol. 15, Iss. 6, pp. 1917-1917
Open Access | Times Cited: 63
The Lancet Breast Cancer Commission
Charlotte E. Coles, Helena Earl, Benjamin O. Anderson, et al.
The Lancet (2024) Vol. 403, Iss. 10439, pp. 1895-1950
Open Access | Times Cited: 59
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression
Aditya Bardia, Hope S. Rugo, Sara M. Tolaney, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 15, pp. 1738-1744
Open Access | Times Cited: 53
Page 1 - Next Page

Scroll to top